Prior to joining the firm, Dr. Dennison conducted graduate and postdoctoral research at the University of Michigan Medical School, where her work focused on protein degradation pathways in the secretory system. Her research incorporated deep mutational scanning, next‑generation sequencing, and bioinformatic analysis to evaluate protein function and cellular quality control mechanisms. She has authored and co‑authored numerous peer‑reviewed publications in leading scientific journals.
Earlier in her career, Dr. Dennison worked in the TB Drug Discovery Group at the Infectious Disease Research Institute in Seattle, where she contributed to identifying novel drug candidates and mechanisms of antibiotic resistance in Mycobacterium tuberculosis. Her experience in industry‑based research informs her practical understanding of therapeutic development and patent strategy.
Dr. Dennison earned her Ph.D. in Molecular and Cellular Biology from the University of Michigan, where she also completed graduate‑level coursework at the University of Michigan Law School and a graduate certificate in Science, Technology and Public Policy. She received her B.A. in Molecular and Cell Biology from the University of California, Berkeley.
